The possible role of complement activation in Alzheimer disease (Q34991850)

5 August 2017

1 reference

title

The possible role of complement activation in Alzheimer disease (English)

1 reference

5 August 2017

0 references

Patrick L McGeer

1 reference

5 August 2017

Edith G McGeer

series ordinal

1 reference

5 August 2017

publication date

1 November 2002

1 reference

Trends in Molecular Medicine

5 August 2017

published in

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

519-523

1 reference

Anti-inflammatory drugs protect against Alzheimer disease at low doses.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Inflammation, autotoxicity and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Use of complement inhibitors in tissue injury

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Molecular and Cellular Characterization of the Membrane Attack Complex, C5b-9, in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Complement activation by beta-amyloid in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Generation of C-reactive protein and complement components in atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Human heart generates complement proteins that are upregulated and activated after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Increased rat cardiac allograft survival by the glycosaminoglycan pentosan polysulfate

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Reactive microgliosis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Brain microglia constitutively express beta-2 integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Chemistry and biochemistry of oxidative stress in neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Set back to Alzheimer vaccine studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Randomized pilot study of nimesulide treatment in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Anti-inflammatory drugs and Alzheimer-type pathology in aging.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902422-X

7 January 2021

10.1016/S1471-4914(02)02422-X

Identifiers

DOI

1 reference

5 August 2017

1 reference